PSS18 ECONOMIC EVALUATION OF A 100% WHEY-BASED, PARTIALLY HYDROLYZED INFANT FORMULA IN THE PREVENTION OF ATOPIC DERMATITIS AMONG SPANISH CHILDREN  by Iskedjian, M et al.
A400 13th Euro Abstracts
differences were found in the tolerability of BTFC and LTFC in the clinical study. 
National unit costs were applied. The time horizon of the model was 3 months. Sensitiv-
ity analyses were performed to test the results responsiveness to changes in key input 
parameters. RESULTS: Signiﬁ cantly more BTFC patients experienced >15% and 
>20% reduction in IOP compared to LTFC (p = 0.003, P < 0.001). Furthermore, 
3-month health care costs for patients treated with BTFC were lower or comparable 
to those of LTFC in the 10 studied countries. Results were largely insensitive to 
changes in key parameters. The cost-effectiveness analyses revealed that BTFC was 
less costly and more effective than LTFC in 8 out of the 10 studied countries (Spain, 
Italy, Germany, UK, The Netherlands, Norway, Sweden and Denmark) and more 
effective at equal health care costs in France and Finland. Therefore, BTFC was a 
dominating treatment strategy in all countries. CONCLUSIONS: BTFC is an effective 
treatment strategy in terms of lowering IOP and is a cost-effective treatment strategy 
for patients with glaucoma.
PSS14
PHARMACOECONOMICS OF INNOVATIVE MEDICINES FOR 
TREATMENT OF PSORIASIS IN UKRAINE
Zalis’ka O, Mandrik O
Danylo Halytsky Lviv National Medical University, Lviv, Ukraine
OBJECTIVES: The objective of this study is to determine the daily and yearly cost 
per treatment of innovative biological preparations. In Ukraine live 46 millions inhab-
itans and the appearance of psoriasis is approximately 2%, 920,000 psoriasis patients. 
It is supposed that at 15–20% appearance of middle and severe of psoriasis there are 
138,000–184,000 patients in Ukraine with degree of the illness. Adult patients with 
moderate to severe plaque form of psoriasis who have not clinical responce for other 
systematic therapies, including cyclosporine, metotrexate and PUVA, or when patients 
are contraindicated for these therapies or are intolerant of them. METHODS: Only 
direct medical cost were calculated from Ukrainian database “Compendium” on 
01.05.2010. Annual treatment costs were calculated based on recommended dosesd 
as per Ukrainian Guidelines from 2007. The costs are presented using third-party 
payer’s perspective, i.e. direct cost to the health system is only considered. In the 
analysis there were three strategies of treatment compared: inﬂ iximab, adalimumab 
and ustekinumab. We used the clinical data of inﬂ iximab, adalimumab, ustekinumab 
from published clinical trials (IMPACT, ADEPT, PHOENIX 1). The cost-effectiveness 
analysis from the payer perspective was conducted. RESULTS: The costs for ﬁ rst year 
of therapy of inﬂ iximab per patient with PASI 75 response are 221998,4 UAH (1 USD 
= 7.92 UAH), of adalimumab—815443,2 UAH, and of ustekinumab −235224,0 UAH. 
In model the cost-effectiveness ratios (average cost per one unit PASI 75response) 
amounted to US$454 for inﬂ iximab, US$1745—adalimumab, US$362—ustekinumab. 
CONCLUSIONS: The cost-effectiveness analysis shows that ustekinumab is more 
cost-effective vs. other innovative biologics for severe psoriasis treatment in Ukraine.
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COST-EFFECTIVENESS OF USTEKINUMAB VS. INFLIXIMAB FOR SEVERE 
PSORIASIS
Omelyanovsky VV1, Avksentieva MV1, Sura MV2, Zorin N2, Hailov P3, Hailov N3
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OBJECTIVES: To evaluate cost-effectiveness of ustekinumab vs. inﬂ iximab for severe 
psoriasis in Russia. METHODS: Cost-effectiveness analysis was performed. The evi-
dence of efﬁ cacy and safety of biologic agents was analyzed. Incremental cost-effec-
tiveness ratio (ICER) was calculated for both biologic agent vs. placebo. Drug costs 
were taken into account. Achievement of PASI 75 was considered to be expected 
outcome, data about efﬁ cacy was extracted from clinical trials. RESULTS: There were 
no trials with direct comparison of ustekinumab and inﬁ ximab. Data from separate 
trials showed that efﬁ cacy of ustekinumab was a little lower than inﬂ iximab at 10–12th 
and 24–28th weeks of treatment. On the contrary at 50–52th week of therapy 
ustekinumab becomes a little more effective than inﬂ iximab. Both biologic agents were 
generally well tolerated in most patients. Calculation of expected costs showed that 
ustekinumab was cheaper than inﬂ iximab if similar periods of follow-up are analyzed. 
At 10–12th weeks of therapy ICER for ustekinumab vs. placebo was a little higher 
than ICER for inﬂ iximab vs. placebo. At 24–28th and 50–52th weeks of therapy ICER 
vs. placebo was lower for ustekinumab. CONCLUSIONS: Ustekinumab is an appro-
priate alternative to inﬂ iximab for patients with severe psoriasis.
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OBJECTIVES: A pharmacoeconomic analysis was performed to determine costs, 
consequences and cost-effectiveness of a speciﬁ c brand of partially hydrolyzed 100% 
whey formula manufactured by Nestlé (PHF-W), in the prevention of atopic dermatitis 
(AD) in “at risk” children when compared to standard cow milk formula (CMF) in 
France. METHODS: An economic model depicting treatment pathways, resource 
utilization and costs associated with the treatment of AD in healthy “at risk” French 
newborns who were not exclusively breastfed was constructed for a 12-month time 
horizon, including an initial six months of formula consumption. Model inputs were 
based on the literature, ofﬁ cial formularies and expert opinion, including outcomes 
from a meta-analysis. The treatment pathways included a dietary management 
approach, a medical treatment approach and a combination thereof. The ﬁ nal 
outcome was the expected cost per avoided case of AD, yielding an incremental cost 
per avoided case (ICER) of AD for PHF-W vs. CMF. Outcomes were presented from 
three perspectives: the French Ministry of Health (MOH), the subject’s family and 
society (SOC). a secondary analysis compared PHF-W to extensively hydrolyzed 
formula (EHF) in prevention. RESULTS: A total of 11,291 AD cases were expected 
to be avoided by selecting PHF-W over CMF in a birth cohort of 156,649 at risk 
infants. The base-case analyses yielded expected ICERs of c2684, -c1474 (savings) 
and c1210 from the MOH, family and SOC perspectives, respectively. Cost drivers 
were the formula from the MOH perspectives, time loss from the family perspective, 
and formula but also to a lesser extent time loss from the SOC perspective. PHF-W 
yielded approximately 81Mc savings against EHF in the secondary analysis. One-way 
and probabilistic sensitivity analyses conﬁ rmed the robustness of the model. 
CONCLUSIONS: Under a range of assumptions, this analysis has established the 
cost-effectiveness of PHF-W in the prevention of AD among French infants.
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OBJECTIVES: A pharmacoeconomic analysis was undertaken to determine costs, 
consequences and cost-effectiveness of a brand of partially hydrolyzed 100% whey 
formula manufactured by Nestlé (PHF-W), in the prevention of atopic dermatitis (AD) 
in “at risk” children when compared to extensively hydrolyzed formula (EHF-Whey 
or Casein) in Denmark. METHODS: Based on a 6-month time horizon for formula 
consumption, an economic model was developed synthesizing treatment pathways, 
resource utilization and costs associated with the treatment of AD in healthy “at risk” 
Danish newborns who were not exclusively breastfed. The cost of formula was 
retrieved from market surveys while other model inputs were obtained from the litera-
ture. a meta-analysis of 6 studies that compared the efﬁ cacy of PHF-W (557 patients) 
and EHF (559 and 580 patients for EHF-Whey and EHF-Casein) yielded RR of 
0.75[0.54,1.05] at 0–12 months and 0.80[0.63,1.02] at 0–36 months for PHF-W vs. 
EHF-Whey and RR of 1.06[0.74,1.53] at 0–12 months and 1.13[0.87,1.47] at 0–36 
months for PHF-W vs. EHF-Casein. Given the evidence for non-signiﬁ cant differences 
between PHF-W and EHF, the analytic approach amounted to a cost-minimization 
analysis reporting the difference in formula acquisition costs. In the base case, it was 
assumed that infants consumed the formula of choice for the full 6 months. In a 
sensitivity analysis, subjects consuming PHF, EHF-Whey or EHF-Casein who devel-
oped AD symptoms were switched to EHF-Whey, EHF-Casein or EHF-Whey, respec-
tively. RESULTS: Savings per child receiving formula of DKK 17,033 were generated 
for PHF-W vs. EHF-Whey while savings of DKK 16,974 were observed for PHF-W 
vs. EHF-Casein. The sensitivity analysis yielded a cost saving of DKK 16,800 with 
PHF-W. CONCLUSIONS: Under a range of assumptions, this analysis demonstrated 
the cost-saving nature of PHF-W vs. both types of EHF in the prevention of AD among 
Danish infants. Further sensitivity analyses, including multivariate, are planned for 
conﬁ rmation of results.
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OBJECTIVES: A pharmacoeconomic analysis was undertaken to determine costs, 
consequences and cost-effectiveness of a speciﬁ c brand of partially hydrolyzed 100% 
whey formula manufactured by Nestlé (PHF-W), in the prevention of atopic dermatitis 
(AD) in “at risk” children when compared to standard cow milk formula (CMF) in 
Spain. METHODS: Based on a 12-month time horizon (including 6 months of formula 
consumption), an economic model was developed synthesizing treatment pathways, 
resource utilization and costs associated with the treatment of AD in healthy “at risk” 
Spanish newborns who were not exclusively breastfed. Model inputs were retrieved 
from the literature, ofﬁ cial formularies and expert opinion, including outcomes from 
a meta-analysis. The treatment pathways considered a dietary management approach, 
a medical treatment approach and a combination thereof. The ﬁ nal outcome was the 
expected cost per avoided case of AD, yielding an incremental cost per avoided case 
(ICER) of AD for PHF-W vs. CMF. Outcomes were presented from three perspectives: 
the Spanish Ministry of Health (MOH), the subject’s family and society (SOC). a 
secondary analysis compared PHF-W to extensively hydrolyzed formula (EHF) in 
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prevention. RESULTS: The expected number of avoided AD cases by selecting PHF-W 
over CMF was 2,787 cases in a birth cohort of 38,661 at risk infants. The base-case 
analyses generated expected ICERs of c1921, -c1102 (savings) and c785 from the 
MOH, family and SOC perspectives, respectively. Cost drivers were formula from the 
MOH perspectives and time loss from the family perspective, with formula and to a 
lesser extent time loss for the SOC perspective. PHF-W yielded approximately c10.7 
million savings against EHF in the secondary analysis. One-way and probabilistic 
sensitivity analyses conﬁ rmed the robustness of the model. CONCLUSIONS: Under 
a range of assumptions, this analysis has established the cost-effectiveness of PHF-W 
in the prevention of AD among Spanish infants.
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OBJECTIVES: Bevacizumab (Avastin) is a promising and low cost treatment of age-
related macular degeneration. Effectiveness and cost-effectiveness might be related to 
the frequency of injections of bevacizumab in the treatment. The standard frequency 
is 4 weeks, while it is uncertain whether lower frequencies lead to different cost and 
effects. METHODS: 170 patients were randomized to 3 treatment frequencies; 4, 6, 
and 8 week intervals between injections. Follow up was 1 year. Vision was measured 
with the Snellen chart, which health states have been valued for QALY analysis. We 
developed a 6 states Markov model with a 12 weeks cycle and a 6-year time-horizon. 
The model included one death state, and ﬁ ve states deﬁ ned by visual acuity(VA) in 
the better seeing eye: VA >20/40, ≤20/40 to >20/80, ≤20/80 to >20/200, ≤20/200 to 
>20/400 and ≤20/400. RESULTS: At time of the (interim) analyses, 72 patients had 
completed the full follow up. The ‘6 weeks’ frequency compared with ‘4 weeks’ shows 
a negative ICER of c6.406, with c1,024 less costs and 0.16 more QALY’s. The ‘8 
weeks’ frequency compared to the 4 weeks frequency shows also a negative ICER of 
c28,032, with c1.543 less costs and 0,06 more QALY’s. When looking at 6 and 8 
weeks, the ‘8 weeks’ has lower costs but is also less effective, with an ICER of c4.946. 
Most uncertainty related to utilities and transition probabilities, while cost contributes 
relatively less to the uncertainty of the outcomes. CONCLUSIONS: Compared with 
4 weeks frequency, the 6 and 8 weeks frequency were dominant, whereas the 8 weeks 
frequency has an ICER in the south west quadrant.
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COST-UTILITY ANALYSIS OF A PRN (AS NEEDED) TREATMENT 
SCHEDULE WITH RANIBIZUMAB (LUCENTIS®) IN WET AMD BASED 
ON CLINICAL EVIDENCE
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OBJECTIVES: To assess whether evidence-based cost-utility of PRN-dosing with 
ranibizumab (Lucentis®, RBZ-PRN) in age-related macular degeneration (AMD) is 
comparable to RBZ-PRN cost-utility estimated previously based on clinical data from 
monthly and quarterly regimens. METHODS: A 10-year MS-Excel Markov model 
with 5 visual acuity (VA) levels and 1 death state predicts VA in patients treated with 
RBZ-PRN, RBZ quarterly (RBZ-Q), RBZ monthly (RBZ-M), Visudyne® photody-
namic therapy (PDT) or best supportive care (BSC). Transition probabilities, adverse 
events and treatment frequencies were provided by newly available PRN-trials 
(SUSTAIN, MONT BLANC) + available trials covering other comparators (ANCHOR, 
MARINA, PIER, EXCITE, TAP). Comparability of populations and treatment effects 
(linear regressions) determined trial data pooling. Final analyses included pooled data 
sets (RBZ-PRN and RBZ-Q) or multiple single-trial data sets (other comparators). 
Secondary analysis included indirect comparison versus pegaptanib sodium (PGB). 
Two-year treatment duration was followed by BSC. Costs (2009, UK health care 
payer, 3.5% discount) were obtained from literature and expert opinion; utilities 
(3.5% discount) from a time-trade-off study. One-way and probabilistic sensitivity 
analyses (SA) covered variability in efﬁ cacy, costs, treatment frequency and utilities. 
RESULTS: Due to lower than predicted injection frequency, clinical trial-based cost-
utility of RBZ-PRN was better than predicted cost-utility. Evidence-based cost-utility 
ranged from £4,414/QALY to £20,489/QALY versus BSC and from dominance to 
£2,383/QALY versus PDT. RBZ-PRN was dominant versus RBZ-Q and versus PGB 
(secondary indirect analysis). RBZ-M was slightly more effective but not cost-effective 
versus RBZ-PRN. The result was most sensitive to time horizon (2–10 y), cost of 
blindness and treatment duration (1–3 y) but conclusions remained throughout 1-way 
SA. Assuming a threshold of £30,000/QALY, the probability that RBZ-PRN is cost-
effective ranged from 68% to 97% versus different comparators. CONCLUSIONS: 
RBZ-PRN using the SUSTAIN and MONT-BLANC re-treatment criteria is cost-
effective compared to other therapies for wet-AMD and represents the most cost-
effective use of RBZ.
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AN ECONOMIC ANALYSIS OF TACROLIMUS OINTMENT 
MAINTENANCE USE (TWICE WEEKLY) VERSUS STANDARD USE IN 
PATIENTS WITH MODERATE TO SEVERE ATOPIC DERMATITIS IN 
NORWAY AND FINLAND
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OBJECTIVES: The objective of this study was to determine the cost-effectiveness of 
tacrolimus ointment used twice weekly as a maintenance treatment regimen compared 
to a standard treatment regimen using tacrolimus twice daily in both adults and 
children with moderate to severe atopic dermatitis (AD) in Norway and Finland. 
METHODS: A decision analytic approach was used to compare costs and outcomes 
of two alternative management strategies for AD over a 12 month treatment period 
for the UK, which was adapted for Norway and Finland. Efﬁ cacy data were used from 
two randomised controlled trials where maintenance use of tacrolimus ointment 
(0.1% in adults and 0.03% in children applied twice weekly) was applied to previously 
affected areas compared to standard use (twice daily application) to treat disease 
exacerbations. Utility data were derived from a published source and cost data were 
taken from public list prices and tariffs in the two countries, Norway and Finland to 
generate cost/QALY. Sensitivity analyses were performed to test the degree of uncer-
tainty around the results. RESULTS: The twice weekly maintenance use of tacrolimus 
ointment resulted in fewer days in disease ﬂ are and improved quality of life versus 
standard treatment with tacrolimus ointment in both adults and children with moder-
ate to severe AD. The twice weekly regimen was cost-saving compared with the 
standard regimen in both Norway and Finland. Sensitivity analyses demonstrated that 
results were largely insensitive to change. CONCLUSIONS: Twice weekly mainte-
nance treatment of moderate and severe AD in both adults and children using tacro-
limus ointment improves health outcomes at a lower cost when compared with the 
reactive treatment strategy using tacrolimus ointment.
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INDIRECT COSTS OF INFORMAL CARE FOR ONE EPISODE OF ACUTE 
OTITIS MEDIA IN GERMANY
Jochum D, Knoll S
GlaxoSmithKline GmbH & Co. KG, Munich, Germany
Indirect costs are not only generated by sick people themselves, but often occur due 
to sick children needing informal care by parents or other informal care givers. Infor-
mal care givers are relatives or friends, not being paid for their services and thereby 
experiencing work, leisure time and productivity loss. Indirect costs induced by infor-
mal care givers are rarely included in CEA, although being part of societal cost. 
OBJECTIVES: This study quantiﬁ ed the indirect costs of an informal care giver caused 
by a sick child suffering from an episode of acute otitis media (AOM) in Germany. 
METHODS: Using a German access panel questionnaires were sent out to households 
with children <5years. The following indirect costs referring to the most recent AOM 
episode of any child were covered: hours of work absence and related costs for 
mothers, fathers and grandparents; loss of leisure time; productivity loss caused by 
solicitousness; work loss compensation by colleagues. RESULTS: A total of 68.3% of 
all parents experienced 7–29 hours of work loss (59.3/9.3% mothers/fathers) per 
episode, grandparents 14 hours (2%). While 40% of parents experienced paid and 
28% unpaid work loss, grandparents being retired caused only unpaid productivity 
losses. Leisure time loss was experienced by all informal caregivers and an average 
was calculated across the total population accounting for c47.39. Indirect costs per 
AOM episode across the total population were in average c411.40 (Sum of: c152.51 
paid, c161.89 unpaid work loss, c209.07 productivity, c47.39 leisure time loss; 
Subtraction of: c45.72 paid, c113.74 unpaid work compensation by a colleague). 
CONCLUSIONS: Indirect costs are mainly included in health economic (HE) analyses 
as paid work loss. For Germany paid work loss only accounted for 38% of total 
indirect costs referring to an AOM episode. Further detailed studies are needed to 
better understand the inﬂ uence of different indirect cost categories across disease areas. 
SENSORY SYSTEMS DISORDERS – Patient-Reported Outcomes Studies
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THE USE AND MISUSE OF ANTIBIOTICS FOR UPPER RESPIRATORY 
TRACT INFECTION
Alawadhi FK
Ministry of Health, UAE, Sharjah, United Arab Emirates
OBJECTIVES: To measure the inﬂ uence of introducing guidelines to doctors and 
educational leaﬂ ets to patients on reducing the level of prescribed antibiotics. To 
investigate the effect of factors such as socio-demographic characteristics, signs, symp-
toms and patient self management. METHODS: Research was conducted in two busy 
clinics, one in Dubai and one in Sharjah. a set of guidelines for the treatment of sore 
throat were extracted from the SIGN guidelines (Appendix 3). The set of guidelines 
was explained to the General Practitioners individually. The guidelines were accom-
panied by a covering paper which explained why and where the guidelines were 
produced. The researcher was based in the nursing room and approached patients 
suffering from a sore throat. These patients were given the educational leaﬂ et and a 
brief explanation of what the leaﬂ et included. The length of explanation depended on 
whether the patient could read or not. They were then asked a set of questions prior 
